[2] [5] These mechanisms collectively improve blood glucose control in patients with type 2 diabetes
In the clinical trial setting Using our PET methodology in a clinical trial setting of T2D patients, we have shown clear differential target engagement of the bimodal GLP-1/glucagon peptide, as shown in Figure 1 [1]
If a GLP-1 is being considered, it should involve thorough screening, clear medical rationale, and close monitoring of nutrition, mood, and eating disorder symptoms
The critical distinctionand one that has received insufficient attention in the oral peptide literatureis between molecules that can accommodate high absorption variability and those for which such variability is clinically unacceptable
Licensing & Accreditation: Gala uses licensed providers and licensed compounding pharmacies and follows HIPAA privacy standards
Here are some of the people who benefit most from peptide therapy at The Good Life IV